International Conference
Erythropoiesis Control and Ineffective Erythropoiesis:
from bench to bedside
Chairs: Maria Domenica Cappellini, Stuart Orkin, Valeria Santini

International Conference
Erythropoiesis Control and Ineffective Erythropoiesis:
from bench to bedside
Information
ABOUT THE CONFERENCE:
The main objective of this conference is to translate recent, novel data from basic research on the origin and developmental control of mega/erythroid progenitors in haematopoiesis to clinical practice. Erythropoiesis is a complex multistep process extending from committed erythroid progenitors to mature red cells and involving a talk to talk process with other haematopoietic progenitors. Although some recent advances now make it possible to characterize some components of erythropoiesis, much still remains to be investigated, in particular as regards pathological erythropoiesis and in the haematological conditions characterized by ineffective erythropoiesis. During erythropoiesis, efficient cytoprotective systems are required to limit possible ROS-related toxic effects: these systems play an even more important role in conditions of ineffective erythropoiesis (IE), such as thalassaemias, sickle cell disease and congenital dyserythropoietic anaemias (CDAs), but also in myelodysplastic syndromes (MDS). Blood transfusion therapy or treatments with erythropoiesis stimulating agents (ESAs), such as recombinant EPO, are so far the frontline therapies for anaemia associated with ineffective erythropoiesis (IE). However, both treatments are not without risk, and in some cases they are not effective. Therefore, there is a clinical need for novel agents supporting IE with different mechanism(s) of action from existing ESAs.
The meeting is structured with the specific aim to be translational “from bench to bedside”, and to involve participants in lively interactive discussions. It offers a unique opportunity to discuss basic science in a clinical context. This approach will notably involve the presentation and discussion of challenging clinical cases.
The two and half day programme includes 9 sessions that will alternate basic science and clinical practice, with a focus on specific diseases such as CDAs, thalassaemia, SCD, haemolytic anaemias and MDS. More specifically session I on erythropoiesis control will elucidate the role of transcription factors, the single cell gene expression in erythroid commitment/development and the proteolytic remodeling of red cell. Session II will focus on the weight of ineffective erythropoiesis in determining the phenotype expression of different diseases (i.e. thalassaemia, SCD, MDS). Session III will complete this comprehensive focus on insights into the molecular causes of ineffective erythropoiesis. Session IV will be very interactive, with a focus on the presentation of case studies characterized by the clinical consequences of IE. Session V is focused on haemoglobin switching which represents an ideal model to improve our understanding of the different mechanisms of gene regulation, especially the mechanisms of switch genes off and on. Session VI will be very clinical with practical advice for the optimal management of emergency events in patients with different types of red cell disorders. The last 3 sessions are dedicated to new therapeutic approaches to erythroid disorders, mainly targeting IE.
The speakers are eminent international experts in their field.
Programme
Read the final programme!
Corporate partners
With the support of*:

Level 1 Conference Partner
*******

Level 2 Conference Partner
*******

Supporting Conference Partner
*******
*ESH conference programmes are developed in strict scientific independence
with no input from corporate sponsors.